Together, these studies have provided new insights into the pathophysiology of osteoporosis, illustrated by the discovery and functional validation of GPC6 and DAAM2. GPC6 may serve as novel drug target for osteoporosis, since it encodes glypican, which is involved in cellular growth control and differentiation. This evidence concerns the gene GPC1 and osteoporosis.